When was ElevateBio founded?

ElevateBio was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is ElevateBio located?

ElevateBio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does ElevateBio have?

As of Mar 31, 2026, the latest employee count at ElevateBio is 493.

Is ElevateBio a funded company?

ElevateBio is a funded company, having raised a total of $1.25B across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 13, 2019.

When was the latest funding round of ElevateBio?

ElevateBio's latest funding was a $***** Series D round on May 24, 2023, with participation from 15 investors.

Where does ElevateBio rank among its competitors?

ElevateBio ranks 12th amongst 531 active competitors, of which 197 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of ElevateBio?

ElevateBio's top competitors include Sana Biotechnology, Spark Therapeutics and Fulcrum Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

ElevateBio - 2026 Company Profile, Team, Funding & Competitors

ElevateBio is a series D company based in Cambridge (United States), founded in 2018 by Mitchell Finer and David Hallal. It operates as a Provider of transnational research for portfolio of cell and gene therapy. ElevateBio has raised $1.25B in funding from investors like Matrix Capital Management, EDBI and Invus. The company has 531 active competitors, including 197 funded and 131 that have exited. Its top competitors include companies like Sana Biotechnology, Spark Therapeutics and Fulcrum Therapeutics.

Company Details

Provider of transnational research for portfolio of cell and gene therapy. It offers transformative therapy along with other translational research like process development, cGMP manufacturing, clinical development, regulatory affairs, and commercial operations.

Website: elevate.bio
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2018

Location

Cambridge, United States

Stage

Series D

Total Funding

$1.25B in 4 rounds

Latest Funding Round

Series D, May 24, 2023, $*****

Investors

Matrix Capital Management & 17 more

Ranked

12^th among 531 active competitors

Employee Count

493 as on Mar 31, 2026

Investment & Acquisitions

LifeEDIT & 2 more

Similar Companies

Sana Biotechnology & 668 more

View ElevateBio's full profile

ElevateBio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ELEVATEBIO MANAGEMENT, INC. CIN: 823981863 , United States, Active	Dec 26, 999	-	468 (As on Dec 31, 2024)	-

ElevateBio has raised a total funding of $1.25B over 4 rounds. Its first funding round was on May 13, 2019. Its latest funding round was a Series D round on May 24, 2023 for $*****. 15 investors participated in its latest round. ElevateBio has 18 institutional investors.

Here is the list of recent funding rounds of ElevateBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 24, 2023	8355122	Series D	3390844	7691187	6141745	4324422
Mar 15, 2021	2185252	Series C	4100440	8833775	1821454	SoftBank Vision Fund & 11 more
Mar 30, 2020	7485972	Series B	5071377	5441094	Invus & 3 more	F2 Ventures & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of ElevateBio's funding rounds and investors

The founders of ElevateBio are Mitchell Finer and David Hallal.

Here are the details of ElevateBio's key team members:

Mitchell Finer: Former Co-Founder of ElevateBio.
David Hallal: Co-Founder of ElevateBio.
Contact Info: 1 email address

View details of ElevateBio's Founder profiles and Board Members

ElevateBio's employee count trend

ElevateBio has 493 employees as of Mar 26. Here is ElevateBio's employee count trend over the years:

Uncover ElevateBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ElevateBio include Sana Biotechnology, Spark Therapeutics and Fulcrum Therapeutics. Here is the list of Top 10 competitors of ElevateBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	74/100
3rd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
4th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 9 others	69/100
9th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	69/100
12th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Fidelity Investments, Citadel & 16 others	69/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on ElevateBio's competitors? Click here to see the top ones

ElevateBio has made 2 investments in Abata and AlloVir and acquired LifeEDIT.

Here is the list of these investments and acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Oct 27, 2021	Acquisition	LifeEDIT	2017	Durham (United States)
Jun 04, 2021	Investments	Abata	2021	Cambridge (United States)
May 21, 2019	Investments	AlloVir	2013	Houston (United States)